Evidence map›Paper›PMID 41847141›Full record

ArticleFrontiers in pharmacology2026

Sertraline safety in adolescents experiencing a depressive episode during first 3 weeks: added anxiolytic matters more than CYP2C19 polymorphisms.

Dmitriy V Ivashchenko, Vitaliy V Sobur, Sergey V Grass, Anna Y Basova, Rimma V Kondratieva, Eugenia N Shagovenko, Yulia V Chernetsova, Svetlana N Tuchkova, Ivan N Korsakov, Sergey I Markov and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Dmitriy V IvashchenkoFederal State Budgetary Research Institution Russian Research Center of Surgery Named After Academician B.V. Petrovsky, Moscow, Russia.
Vitaliy V SoburScientific-Practical Children's and Adolescents Mental Health Center n.a. G.E. Sukhareva, Moscow, Russia.
Sergey V GrassScientific-Practical Children's and Adolescents Mental Health Center n.a. G.E. Sukhareva, Moscow, Russia.
Anna Y BasovaScientific-Practical Children's and Adolescents Mental Health Center n.a. G.E. Sukhareva, Moscow, Russia.
Rimma V KondratievaScientific-Practical Children's and Adolescents Mental Health Center n.a. G.E. Sukhareva, Moscow, Russia.
Eugenia N ShagovenkoScientific-Practical Children's and Adolescents Mental Health Center n.a. G.E. Sukhareva, Moscow, Russia.
Yulia V ChernetsovaScientific-Practical Children's and Adolescents Mental Health Center n.a. G.E. Sukhareva, Moscow, Russia.
Svetlana N TuchkovaFederal State Budgetary Research Institution Russian Research Center of Surgery Named After Academician B.V. Petrovsky, Moscow, Russia.
Ivan N KorsakovFederal State Budgetary Research Institution Russian Research Center of Surgery Named After Academician B.V. Petrovsky, Moscow, Russia.
Sergey I MarkovFederal State Budgetary Research Institution Russian Research Center of Surgery Named After Academician B.V. Petrovsky, Moscow, Russia.
Karin B MirzaevFederal State Budgetary Research Institution Russian Research Center of Surgery Named After Academician B.V. Petrovsky, Moscow, Russia.
Yuriy S ShevchenkoRussian Medical Academy of Continuous Professional Education, Moscow, Russia.
Dmitry SychevFederal State Budgetary Research Institution Russian Research Center of Surgery Named After Academician B.V. Petrovsky, Moscow, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: To evaluate the associations of clinical and pharmacogenetic factors (CYP2C19*2, *17 polymorphisms) with the safety parameters of sertraline in adolescents with a depressive episode and suicidal intentions for 3 weeks in a psychiatric hospital. Methods: The study included 112 adolescents, who were hospitalized due to a depressive episode and suicidal intentions. All patients received sertraline for 21 days. The safety of pharmacotherapy was assessed on the 7th and 21st day using the Antidepressant ADRs checklist. Each patient underwent genetic testing for Results: It was found that patients with the Conclusion: Polypharmacy (particularly, adding a non-benzodiazepine anxiolytic) was a more significant risk factor for ADRs when taking sertraline, compared to the carrier status of CYP2C19 gene polymorphisms.

Indexed as

CYP2C19depressiongenegeneticsgenomegenotypesafetysertraline

Identifiers

PMID41847141
PMCPMC12989821

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.